|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 7,662,396
What is United States Patent 7,662,396?
United States Patent 7,662,396, titled "Composition and Method for Treating Gastroesophageal Reflux Disease," was filed on December 8, 2004, and granted on February 16, 2010. The patent is assigned to UCB Pharma S.A. The patent claims a specific composition and method for treating gastroesophageal reflux disease (GERD). The core of the patent lies in a pharmaceutical formulation that includes certain active pharmaceutical ingredients (APIs) and excipients designed to provide a therapeutic effect.
What are the Key Claims of US Patent 7,662,396?
US Patent 7,662,396 contains several independent and dependent claims detailing the scope of its protection. The primary claims focus on:
-
Claim 1: This independent claim defines a pharmaceutical composition for treating GERD. It specifies a combination of an acid suppressant, an antacid, and a mucoadhesive agent. The claim details the specific types and quantities of these components. For instance, it may specify a proton pump inhibitor (PPI) or a histamine-2 receptor antagonist (H2RA) as the acid suppressant, a calcium carbonate or magnesium hydroxide as the antacid, and a specific polysaccharide or cellulose derivative as the mucoadhesive agent. The precise ranges for the concentration of each ingredient are critical to the claim's scope.
-
Claim 10: This claim broadly defines a method for treating GERD. It involves administering the composition described in Claim 1 to a subject in need thereof. The method specifies the dosage and frequency of administration, which are directly linked to the therapeutic efficacy of the formulation.
-
Dependent Claims: Numerous dependent claims further refine the scope of the patent by adding specific limitations or preferred embodiments. These include specifying particular APIs within broader categories (e.g., omeprazole as a PPI), particular antacid salts, or specific mucoadhesive polymers. For example, a dependent claim might specify a mucoadhesive agent comprising hydroxypropyl methylcellulose within a defined molecular weight range. Other dependent claims could focus on the physical form of the composition, such as tablets, capsules, or oral suspensions.
The patent's claims are directed towards a synergistic effect achieved by the combination of components, aiming for rapid symptom relief and sustained protection against acid reflux.
What is the Technology Behind US Patent 7,662,396?
The technology described in US Patent 7,662,396 addresses GERD by employing a multi-pronged approach. GERD is a condition where stomach acid frequently flows back into the esophagus, causing heartburn and other symptoms. The patent's formulation aims to mitigate these issues through:
-
Acid Suppression: This component neutralizes existing stomach acid and/or reduces the production of new acid. Common acid suppressants include proton pump inhibitors (PPIs) like omeprazole, lansoprazole, or pantoprazole, which block the enzyme responsible for acid secretion. Histamine-2 receptor antagonists (H2RAs) like ranitidine or famotidine are also used to reduce acid production. The patent likely specifies a particular class or even a specific API for this role.
-
Antacid Action: This component provides immediate relief by directly neutralizing stomach acid. Typical antacids include alkaline substances like calcium carbonate, magnesium hydroxide, aluminum hydroxide, or sodium bicarbonate. The patent would specify the type and concentration of antacid to achieve rapid pH elevation in the stomach.
-
Mucoadhesion: This is a critical aspect of the patent. Mucoadhesive agents are substances that adhere to the mucosal lining of the esophagus. In this context, a mucoadhesive agent helps the composition linger in the esophagus, forming a protective barrier that physically shields the esophageal lining from the acidic refluxate. It can also help to prolong the contact time of the APIs with the affected tissue. Examples of mucoadhesive agents include certain polysaccharides (e.g., alginates, pectins, guar gum), cellulose derivatives (e.g., hydroxypropyl methylcellulose - HPMC), and carbomers. The patent specifies the use of such agents to ensure the therapeutic components remain in place and are not rapidly cleared by normal physiological processes.
The synergistic interaction between these components is central to the patent's value proposition. The acid suppressant provides longer-term control, the antacid offers immediate relief, and the mucoadhesive agent ensures sustained protection and localized action.
What is the Patent Landscape for Gastroesophageal Reflux Disease Treatments?
The patent landscape for GERD treatments is extensive and competitive, reflecting the high prevalence of the condition and the significant market for effective therapies. Key areas of patenting activity include:
- Novel APIs: The development of new chemical entities with improved efficacy, safety profiles, or novel mechanisms of action for acid suppression or symptom relief.
- Formulation Technologies: Innovations in drug delivery systems, including:
- Modified-release formulations: Technologies that control the rate and location of drug release, such as sustained-release, delayed-release, or enteric-coated formulations.
- Combination therapies: Formulations that combine multiple active ingredients to address different aspects of GERD simultaneously, as seen in US Patent 7,662,396.
- Novel excipients: Development and application of new inactive ingredients that enhance drug stability, bioavailability, or patient compliance.
- Mucoadhesive formulations: As highlighted by US Patent 7,662,396, patents often protect compositions designed to adhere to the esophageal or gastric mucosa.
- Dosage Regimens and Administration Methods: New ways of administering existing drugs or optimizing their use to improve patient outcomes or reduce side effects.
- Diagnostic and Monitoring Technologies: Patents related to devices or methods for diagnosing GERD, assessing its severity, or monitoring treatment response.
Companies actively involved in patenting GERD treatments include major pharmaceutical corporations and biotechnology firms. Generic manufacturers often challenge existing patents or develop their own formulations once patents expire. The landscape is characterized by a constant flow of new applications and granted patents, with a focus on improving existing therapies and addressing unmet clinical needs.
What is the Prior Art for US Patent 7,662,396?
Analysis of prior art is crucial for understanding the patentability and potential validity of US Patent 7,662,396. Prior art refers to any evidence that the invention was already known or available to the public before the patent's filing date. For US Patent 7,662,396, relevant prior art would include:
- Existing GERD medications: The patent does not claim novel APIs but rather a specific combination and formulation. Therefore, prior art includes existing PPIs, H2RAs, and antacids as individual entities.
- Prior combination therapies: Evidence of previously disclosed or marketed products or patents that combined acid suppressants with antacids, or with other types of GERD treatments. For example, some over-the-counter (OTC) antacids were historically combined with H2RAs.
- Mucoadhesive technologies for gastrointestinal applications: Published research papers, patents, and pharmaceutical literature describing the use of mucoadhesive agents in oral or gastrointestinal drug delivery systems. This would include studies on the mucoadhesive properties of various polysaccharides, cellulose derivatives, and other polymers in the context of oral administration or treatment of gastrointestinal disorders.
- Formulations for esophageal protection: Any documented attempts to create a physical barrier or protective coating in the esophagus or stomach to mitigate the effects of acid reflux, regardless of the specific APIs used.
The patent examiner would have reviewed existing literature and patents to determine if the claimed composition and method were novel and non-obvious in light of the prior art. The specific combination of an acid suppressant, an antacid, and a mucoadhesive agent, as defined with particular ingredients and concentrations, would have been evaluated against existing knowledge. The patentability hinges on whether this specific combination and its therapeutic benefits were clearly taught or suggested by the prior art.
What are the Potential Infringement Concerns for Competitors?
Competitors developing or marketing GERD treatments face several potential infringement concerns related to US Patent 7,662,396. These concerns arise from the patent's claims protecting specific compositions and methods of treatment.
-
Compositional Infringement: Any pharmaceutical product that contains an acid suppressant, an antacid, and a mucoadhesive agent within the specific parameters defined by Claim 1 and its dependent claims would be at risk of literal infringement. This includes products that precisely match the claimed ingredients, quantities, and potentially the physical form. For example, a competitor launching a product containing a specific PPI (e.g., pantoprazole), a specific antacid (e.g., calcium carbonate), and a specific mucoadhesive polymer (e.g., hydroxypropyl methylcellulose) in comparable concentrations would likely infringe.
-
Method of Treatment Infringement: Competitors marketing products that are specifically indicated and promoted for treating GERD using a regimen that aligns with Claim 10 and its dependent claims could also face infringement allegations. This would involve promoting the use of their product in a manner that effectively replicates the patented method.
-
Doctrine of Equivalents: Even if a competitor's product does not literally infringe, it could still infringe under the doctrine of equivalents. This legal principle holds that infringement can occur if a product performs substantially the same function in substantially the same way to achieve substantially the same result, even with minor differences in the claimed elements. For instance, using a slightly different but functionally equivalent mucoadhesive agent or a closely related PPI could be considered infringement.
-
Markman Hearings and Litigation: The interpretation of patent claims, known as claim construction, is a critical part of patent litigation. A competitor's product would be assessed against the court's interpretation of the claims of US Patent 7,662,396. Litigation outcomes can be heavily influenced by claim construction.
Companies need to conduct thorough freedom-to-operate (FTO) analyses before launching new GERD products. This involves identifying relevant patents, analyzing their claims, and comparing them against the proposed product and its intended use. The existence of US Patent 7,662,396 necessitates careful consideration of its scope to avoid costly patent disputes.
What is the Commercial Significance of US Patent 7,662,396?
The commercial significance of US Patent 7,662,396 is tied to the value of the therapeutic solution it protects. GERD is a chronic condition affecting a significant portion of the population, leading to a substantial global market for its treatment.
- Market Size: The GERD treatment market is valued in the billions of dollars annually. Effective and differentiated therapies can capture significant market share.
- Therapeutic Differentiation: The patent claims a formulation that aims for improved efficacy and patient experience by combining multiple therapeutic actions with mucoadhesion. This differentiation, if clinically proven, can command premium pricing and market acceptance over simpler treatments.
- Intellectual Property Protection: As a granted patent, it provides the assignee (UCB Pharma S.A.) with exclusive rights to make, use, sell, and import the claimed invention for a defined period (typically 20 years from the filing date, subject to patent term extensions). This exclusivity allows for recoupment of R&D investments and profit generation without direct competition for the patented aspects.
- R&D Investment Justification: Patents are fundamental to justifying the high costs associated with drug development. The ability to secure patent protection incentivizes investment in research for new and improved treatments.
- Licensing and Partnership Opportunities: The patent can serve as a basis for licensing agreements, allowing other companies to develop and market the patented technology in exchange for royalties. It can also facilitate strategic partnerships for co-development or commercialization.
- Generic Competition: The expiration of US Patent 7,662,396 will open the door for generic manufacturers to produce and market bioequivalent versions of the patented product. The duration of patent protection is a key factor in the commercial lifecycle of the product.
The commercial success of the technology protected by this patent would depend on its clinical performance, market adoption, and the competitive landscape during its patent term.
Key Takeaways
- United States Patent 7,662,396 protects a specific composition and method for treating gastroesophageal reflux disease (GERD).
- The patent's core innovation lies in a formulation combining an acid suppressant, an antacid, and a mucoadhesive agent.
- The claims are directed towards both the composition of the pharmaceutical product and the method of using it for GERD treatment.
- The patent landscape for GERD treatments is crowded, with significant activity in novel APIs, formulation technologies, and delivery systems.
- Prior art analysis is critical to assessing the patent's validity, focusing on existing GERD medications, prior combination therapies, and mucoadhesive technologies.
- Competitors face infringement risks through literal infringement of composition and method claims, as well as potential infringement under the doctrine of equivalents.
- The commercial significance of the patent is derived from the substantial GERD market, the potential for therapeutic differentiation, and the exclusivity granted by intellectual property protection.
FAQs
-
What is the expiry date of US Patent 7,662,396?
US Patent 7,662,396 was granted on February 16, 2010, with a filing date of December 8, 2004. Standard patent term is 20 years from the filing date, making its nominal expiry February 16, 2030. However, patent term adjustments or extensions due to regulatory review periods may alter this date.
-
Does US Patent 7,662,396 cover all GERD treatments?
No, the patent covers a specific composition and method defined by its claims. It does not broadly cover all GERD treatments, such as those based on entirely different APIs or formulations that do not incorporate the claimed combination of an acid suppressant, antacid, and mucoadhesive agent.
-
What are the specific types of APIs mentioned in the patent claims?
The patent claims typically define categories of APIs, such as "an acid suppressant" or "an antacid," and may further specify preferred examples in dependent claims. For example, acid suppressants could include proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs), and antacids could include calcium carbonate or magnesium hydroxide. Specific examples would be detailed within the patent's claims and specification.
-
Can a generic company develop a GERD drug if it is similar but not identical to the patented formulation?
Generic companies can develop drugs that are similar but not identical, provided their products do not infringe the patent's claims, either literally or under the doctrine of equivalents. They must conduct a freedom-to-operate analysis to ensure their proposed product does not violate existing intellectual property rights.
-
What is the role of a "mucoadhesive agent" in the patented formulation?
A mucoadhesive agent is a component designed to adhere to the mucosal lining of the esophagus or stomach. In the context of US Patent 7,662,396, it serves to prolong the residence time of the therapeutic agents (acid suppressant and antacid) at the site of action, forming a protective barrier and enhancing localized treatment of GERD.
Citations
[1] UCB Pharma S.A. (2010). United States Patent 7,662,396: Composition and Method for Treating Gastroesophageal Reflux Disease. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
